SKB BIO-B (06990) announced multiple innovative drug research results at the European Oncology Congress in 2025.
Colembato biology-B (06990) announced that the company has been exhibited in Berlin, Germany from October 17th to 21st...
SKB BIO-B (06990) announced that the company has presented multiple clinical research findings at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany from October 17th to 21st. The research covers targeted antibody-drug conjugates (ADCs) including sacituzumab govitecan (Trodelvy) targeting TROP2, ado-trastuzumab emtansine (Kadcyla) targeting HER2, and data related to SKB315, an ADC targeting Claudin18.2 (CLDN18.2).
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
